4 assets in Tracheal Cancer

Therapeutic assets addressing Tracheal Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Tracheal Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Tracheal Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- Tracheal Cancer	VM Oncology, LLC	P1/2	CCC (48)
Pembrolizumab Tracheal Cancer	VM Oncology, LLC	P1/2	CCC (48)